Two-thirds of the public say they are very or somewhat worried about being told they have the disease – higher than for any other medical condition, including dementia and having a heart attack – according to polling released today.
Amgen gives first glimpse at PRMT5 inhibitor, days after Bristol Myers put a $1B promise on the target
In a first look at Amgen’s experimental PRMT5 inhibitor, roughly 16% of patients with various cancers saw their tumors shrink by at least 30%, equating
October 14, 2023